anti braf mouse igg  (Santa Cruz Biotechnology)

Journal: Oncology Letters

Article Title: Analysis of the clonal origin and differences in the biological behavior of multifocal papillary thyroid carcinoma

doi: 10.3892/ol.2024.14677

Figure Lengend Snippet: Histology of individual multifocal papillary thyroid carcinoma samples. Representative images of (A) BRAF protein-positive, (B) BRAF protein-negative, (C) TERT protein-positive and (D) TERT protein-negative samples. Magnification, ×40. BRAF, v-raf murine sarcoma viral oncogene homolog B1; TERT, telomerase reverse transcriptase.

Article Snippet: The primary antibodies used were mouse anti-human BRAF monoclonal antibody (cat no. TA500431) and rabbit anti-human TERT polyclonal antibody (cat. no. TA324097), both from OriGene Technologies, Inc, a dilution of 1:200.

Techniques: Reverse Transcription

Journal: Oncology Letters

Article Title: Analysis of the clonal origin and differences in the biological behavior of multifocal papillary thyroid carcinoma

doi: 10.3892/ol.2024.14677

Figure Lengend Snippet: BRAF V600E mutation in multifocal papillary thyroid carcinoma. Representative (A) BRAF V600E mutant and (B) wild-type amplification plots generated using quantitative PCR. The red marking represents the threshold line. BRAF, v-raf murine sarcoma viral oncogene homolog B1; BRAF-IC, BRAF internal reference gene detection curve; BRAF-W, BRAF V600E wild-type gene detection curve; BRAF-M, BRAF V600E mutation gene detection curve; DRn, change in relative fluorescence normalized.

Article Snippet: The primary antibodies used were mouse anti-human BRAF monoclonal antibody (cat no. TA500431) and rabbit anti-human TERT polyclonal antibody (cat. no. TA324097), both from OriGene Technologies, Inc, a dilution of 1:200.

Techniques: Mutagenesis, Amplification, Generated, Real-time Polymerase Chain Reaction, Fluorescence

Journal: Oncology Letters

Article Title: Analysis of the clonal origin and differences in the biological behavior of multifocal papillary thyroid carcinoma

doi: 10.3892/ol.2024.14677

Figure Lengend Snippet: Gene mutation and protein expression in cases of multifocal papillary thyroid carcinoma with different clonal origins.

Article Snippet: The primary antibodies used were mouse anti-human BRAF monoclonal antibody (cat no. TA500431) and rabbit anti-human TERT polyclonal antibody (cat. no. TA324097), both from OriGene Technologies, Inc, a dilution of 1:200.

Techniques: Mutagenesis, Expressing

Journal: bioRxiv

Article Title: Deleting PTEN, but not SOCS3 or myelin inhibitors, robustly boosts BRAF-elicited intraspinal regeneration of peripheral sensory axons

doi: 10.1101/2024.09.18.613685

Figure Lengend Snippet: (A) A schematic diagram of the experimental procedure for 3 week analysis of all transgenic lines. Boxed area specifies region of interest in the spinal cord. (B) tdTomato expression indicates high transgene activation within sensory neurons and afferent projections of the dorsal horn and dorsal columns. Scale bar: 200 μm , 100 μm . (C) Western blot analysis confirms expression of BRAF V600E in kaBRAF iTg but not WT DRG lysates. Total B-RAF protein levels remain unchanged. Molecular mass is noted in kilodaltons. Cross sections of WT (D-D”) or kaBRAF iTg (E-E”’) groups show GFP-labeled axon regeneration at 3 weeks after DR crush injury. WT show spontaneous regeneration along the DR but no regeneration past the DREZ. (E”’, inset) kaBRAF expression promotes axon regeneration across the DREZ and into the superficial laminae of the spinal cord. GFAP staining denotes the astrocytic boundary of the CNS. Dotted line indicates the relative area of the DREZ. (F) Quantification of axon growth shows significantly more axons penetrate the DREZ in kaBRAF iTg than in WT controls. Scale bar: D-E” =100 μm, E”’ = 50 μm. n=4-5 mice per group, at least 5-6 sections per mouse, **** P < 0.0001, ** P < 0.01, two-way ANOVA with Sidak’s multiple comparisons test. Values represent mean ±SEM.

Article Snippet: Antibodies used were mouse anti-BRAF V600E (1:1000, Spring Bioscience), rabbit anti-BRAF (1:1000, Cell Signaling #9433), rabbit anti-PTEN (1:1000, Cell Signaling, #9559), rabbit anti-pS6 (1:1000, Cell Signaling #2215), rabbit anti-survivin (1:1000, CST #2808), and mouse anti-β-actin (1:5000, Sigma, A5441).

Techniques: Transgenic Assay, Expressing, Activation Assay, Western Blot, Labeling, Staining

Journal: Oncology Letters

Article Title: Analysis of the clonal origin and differences in the biological behavior of multifocal papillary thyroid carcinoma

doi: 10.3892/ol.2024.14677

Figure Lengend Snippet: Figure 1. Histology of individual multifocal papillary thyroid carcinoma samples. Representative images of (A) BRAF protein‑positive, (B) BRAF protein‑ negative, (C) TERT protein‑positive and (D) TERT protein‑negative samples. Magnification, x40. BRAF, v‑raf murine sarcoma viral oncogene homolog B1; TERT, telomerase reverse transcriptase.

Article Snippet: The primary antibodies used were mouse anti‐human BRAF monoclonal antibody (cat no. TA500431) and rabbit anti‐human TERT polyclonal antibody (cat. no. TA324097), both from OriGene Technologies, Inc, a dilution of 1:200.

Techniques: Reverse Transcription

Journal: Oncology Letters

Article Title: Analysis of the clonal origin and differences in the biological behavior of multifocal papillary thyroid carcinoma

doi: 10.3892/ol.2024.14677

Figure Lengend Snippet: Figure 2. BRAF V600E mutation in multifocal papillary thyroid carcinoma. Representative (A) BRAF V600E mutant and (B) wild‑type amplification plots generated using quantitative PCR. The red marking represents the threshold line. BRAF, v‑raf murine sarcoma viral oncogene homolog B1; BRAF‑IC, BRAF internal reference gene detection curve; BRAF‑W, BRAF V600E wild‑type gene detection curve; BRAF‑M, BRAF V600E mutation gene detection curve; DRn, change in relative fluorescence normalized.

Article Snippet: The primary antibodies used were mouse anti‐human BRAF monoclonal antibody (cat no. TA500431) and rabbit anti‐human TERT polyclonal antibody (cat. no. TA324097), both from OriGene Technologies, Inc, a dilution of 1:200.

Techniques: Mutagenesis, Amplification, Generated, Real-time Polymerase Chain Reaction, Fluorescence